Business Context and Reporting Period
Company: Orthofix International N.V. (Orthofix Medical Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: Orthofix is a multinational corporation designing, developing, manufacturing, and distributing medical equipment for the orthopedics market. The company operates through four reportable segments: Domestic, Spinal Implants and Biologics, Breg, and International. As of October 10, 2010, the company became a Curaçao legal entity following the dissolution of the Netherlands Antilles.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Net Sales | $138,906 | $420,573 |
| Gross Profit | $106,640 | $321,527 |
| Gross Margin | 76.8% | 76.4% |
| Operating Income | $18,994 | $72,149 |
| Net Income | $8,520 | $36,244 |
| Diluted EPS | $0.48 | $2.03 |
| Cash and Cash Equivalents | $15,248 | $15,248 (Balance Sheet) |
| Restricted Cash | $21,987 | $21,987 (Balance Sheet) |
| Total Debt (Current + Long-term) | $225,121 | $225,121 (Balance Sheet) |
| Operating Cash Flow (9 Months) | N/A | $19,412 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3% ($3.8M) for the quarter and 5% ($19.0M) for the nine months compared to the prior year periods. Growth was driven by the Domestic and Spinal Implants and Biologics segments, offset by declines in the International and Breg segments.
- Profitability: Net income increased 38% for the quarter and 141% for the nine months. The nine-month increase was significantly bolstered by a one-time net gain of $12.3 million from the sale of vascular operations.
- Segment Performance:
- Domestic: Sales up 9% (Q3) and 10% (9M) due to growth in Spine and Orthopedics sectors.
- Spinal Implants and Biologics: Sales up 19% (Q3) and 10% (9M), driven by Firebird pedicle screw system and Trinity Evolution allograft.
- International: Sales down 17% (Q3) and 3% (9M), impacted by the disposal of vascular operations and foreign currency fluctuations.
- Breg: Sales down 4% (Q3 and 9M) due to declines in bracing and cold therapy products.
- Debt Refinancing: In August 2010, the company entered a new credit agreement, replacing the old facility. This reduced the effective interest rate from 8.8% to 3.5% and resulted in a $0.6 million loss on refinancing due to the write-off of old debt issuance costs.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Sale of Vascular Operations: Recorded a net gain of $12.3 million in the nine months ended September 30, 2010, from the sale of the A-V IMPULSE SYSTEM assets to Covidien.
- Legal Expenses: General and administrative expenses included approximately $3.7 million in legal fees related to investigations into the bone growth stimulation industry and an internal FCPA investigation regarding a Mexican subsidiary (Promeca).
- Outlook: Management expects revenue growth driven by new product launches (Trinity Evolution, Firebird, Pillar SA, Ascent LE) and improved gross margins. The company anticipates meeting financial covenants under the new credit agreement (leverage ratio < 3.25; fixed charge coverage > 1.25).
- Risks and Contingencies:
- Legal Proceedings: Ongoing government investigations (DOJ, HHS) regarding physician compensation and marketing practices. Multiple qui tam lawsuits are pending or on appeal.
- FCPA Investigation: Internal investigation into potential improper payments by the Mexican subsidiary is in early stages; potential sanctions include fines and disgorgement.
- Product Liability: Breg faces numerous lawsuits alleging chondrolysis from local infusion pumps divested in 2008.
- Patent Litigation: NuVasive and Osiris have sued alleging patent infringement regarding the Trinity Evolution allograft.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the new credit agreement's leverage (2.0x) and fixed charge coverage (2.9x) ratios.
- Legal Exposure: Monitor the status of the DOJ/HHS investigations and the outcome of the qui tam appeals, as these could result in significant fines or settlements.
- FCPA Investigation: Track the progress of the internal investigation into Promeca S.A. DE C.V. for potential financial penalties or operational restrictions.
- Escrow Fund: Review the status of the $52 million escrow fund from the Blackstone merger, as the company is contesting indemnification claims against former shareholders.
- Patent Defense: Assess the company's defense strategy against the NuVasive/Osiris patent infringement claim regarding the Trinity Evolution product.